A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma
Latest Information Update: 03 Jul 2025
At a glance
- Drugs BTX A51 (Primary)
- Indications Liposarcoma; Sarcoma
- Focus Adverse reactions
Most Recent Events
- 26 Jun 2025 Study protocol amended with addition of sarcoma population. Arms increased from 1 to 2.
- 26 Jun 2025 Planned number of patients changed from 12 to 24.
- 28 Apr 2025 According to Edgewood Oncology media release, new preclinical efficacy data supporting this trial, from an Investigator-Sponsored preclinical Study of BTX-A51 in liposarcoma models, has been presented at the American Association of Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025, in Chicago. These data further support the ongoing clinical advancement of BTX-A51 in this investigator-sponsored Phase 1 pilot study.